
Vistim Labs turns a single EEG into PET-like estimates of amyloid, tau, and cognitive decline so clinicians can monitor dementia progression and therapy response. Their B2B SaaS product, CASBA ATN+,…

Vistim Labs turns a single EEG into PET-like estimates of amyloid, tau, and cognitive decline so clinicians can monitor dementia progression and therapy response. Their B2B SaaS product, CASBA ATN+,…
Tech: EEG-based PET-like biomarker estimation (amyloid, tau, neurodegeneration) via AI/ML
Product: CASBA ATN+ / Ceregram — in-clinic, noninvasive longitudinal brain monitoring
Founded: 2021
HQ / Bases: United States (Salt Lake City listed); additional bases referenced (Miami, San Diego) and affiliates (New York, Paris, Berlin)
Funding: Grant-backed funding; total reported ~$817,000
Neurodegenerative disease monitoring and clinical/research brain mapping
2021
Biotechnology Research
Multiple grant funding transactions listed; Crunchbase classifies last round as Grant with Alberta Innovates as lead
“Alberta Innovates; other supporters listed include Beresford Ventures, GoAhead Ventures, PharmStars, RK Hart Capital”
| Company |
|---|
Drive Capital Formation for Breakthrough MedTech in Alzheimer’s Brain Imaging
Vistim Labs has developed a category-defining technology: in-clinic routine brain imaging. This way, we can answer the question that matters most: is therapy working ? Our propriatery technique works by converting routine EEGs into high-resolution, PET-like brain images — without radiation and entirely in-office. Our platform enables objective monitoring of amyloid/tau clearance and disease progression, giving neurologists and patients the clarity they’ve never had before.
We seek a fractional CFO with deep experience in early-stage MedTech fundraising to help us scale efficiently and successfully.
This is a high-impact, hands-on role for someone who thrives in the earliest stages of company building. You will partner directly with the founders to shape our financial strategy, prepare for institutional capital, and build the infrastructure needed to support rapid commercial growth.
Why This Role Matters Now
Vistim Labs sits at the intersection of two massive tailwinds: the explosion of new Alzheimer’s therapies and the urgent need for better, more accessible diagnostics/monitoring tools. Clinics are adopting our technology because it solves real problems — affordability, accessibility, and radiation-free imaging. To accelerate this mission and reach more patients, we need world-class capital formation expertise.
Your Role
Lead capital formation strategy and execution for our current and future fundraising rounds (Seed/Series A range).
Build and maintain strong relationships with medtech, digital health, and life sciences investors.
What We’re Looking For
Proven track record raising capital for early-stage medtech, diagnostics, or neurology-related companies (multiple successful rounds preferred).
Strong existing network in medtech and life sciences venture capital.
You do not need to be a full-time, in-house CFO. We are explicitly seeking a high-caliber fractional partner who can commit 15–25 hours per week initially, with flexibility as we grow.
If you have successfully helped early-stage medtech companies raise meaningful capital, built investor confidence, and established financial excellence in resource-constrained environments, we want to talk.
This is a rare opportunity to join a mission-driven team at the exact moment when our technology can meaningfully improve dementia care — and to help shape the financial future of one of the most exciting neurodiagnostic advances in the last decade.
Interested candidates should reply with a brief note, your relevant fundraising experience, and references/referrals from prior medtech engagements. We review all serious inquiries personally.
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
81,000+
Open Roles
4,600+
New This Week
Prepare all fundraising materials: pitch decks, financial models, data rooms, cap tables, and due diligence packages.
Develop financial strategy, forecasting, budgeting, and scenario planning tailored to a high-growth medtech startup.
Establish proper financial infrastructure, controls, and reporting systems suitable for a post-seed company entering commercial scale.
Advise on equity/debt structures, valuation, term sheets, and corporate governance.
Support M&A, strategic partnerships, and grant/non-dilutive funding opportunities where relevant.
Experience as a fractional CFO or full-time CFO/controller in a similar-stage startup (post-seed, pre-revenue to early commercial).
Deep understanding of medtech regulatory, reimbursement, and commercial pathways.
Ability to operate at both strategic and tactical levels — you’re comfortable building models one day and sitting in investor meetings the next.
High integrity, excellent communication skills, and the ability to represent the company credibly to sophisticated investors.
Strong referrals from founders and investors you’ve previously worked with.